Correlation of antiviral antibodies and morphological changes in bladder cancer patients

Cover Page

Cite item

Full Text

Abstract

Currently, the task of searching for prognostic criteria of disease progression and recurrence of bladder cancer is extremely important. Objective. To evaluate the correlation of the level of antiviral antibodies and morphological changes in bladder cancer. Materials and methods. The examination and treatment of 100 patients (72 men and 28 women), aged from 38 to 90 years (mean age 65±10) with referral diagnosis of bladder cancer. Additionally performed: a blood test for IgG, M to herpes (HSV) type 1 and 2, cytomegalovirus (CMV), the virus Epstein-Barr (EBV). The tumor tissue and urine of patients taken for PCR diagnosis of viruses HSV 1 and 2 types, high-risk types of HPV, CMV, EBV. Results. Levels of antiherpetic antibodies are set for morphological changes in the form of koilocytosis, degradation of the surface of the tumor cells, perivascular lymphoid infiltration, the presence of lymphocytes in tumors as prognostic factors of tumor processwhich only start to appear. Specified levels of antiviral antibodies, according to which it is possible to predict the recurrent nature of the tumor and polyvocality lesions of the bladder wall. Conclusions. The correlation of the level of antiviral antibodies and morphological changes that allow with high probability to predict the course of neoplastic process.

About the authors

I. V Kosova

City Clinical Hospital №68 of the Department of Health of Moscow

Email: kosovainga@mail.ru
канд. мед. наук, врач-уролог урологического отд-ния ГБУЗ ГКБ №68 109263, Russian Federation, Moscow, ul. Shkuleva, d. 4

O. B Loran

Russian Medical Academy of Continuous Professional Education of the Ministry of Health of the Russian Federation

Email: oleg_loran@gmail.com
акад. РАН, д-р мед. наук, проф. каф. урологии и хирургической андрологии ФГБОУ ДПО РМАНПО 125993, Russian Federation, Moscow, ul. Barrikadnaia, d. 2/1

L. A Sinyakova

Russian Medical Academy of Continuous Professional Education of the Ministry of Health of the Russian Federation

Email: l.a.sinyakova@mail.ru
д-р мед. наук, проф. каф. урологии и хирургической андрологии ФГБОУ ДПО РМАНПО 125993, Russian Federation, Moscow, ul. Barrikadnaia, d. 2/1

L. V Gundorova

City Clinical Hospital №68 of the Department of Health of Moscow

Email: ludovik-213@mail.ru
д-р мед. наук, зав. патологоанатомическим отд-нием ГБУЗ ГКБ №68 109263, Russian Federation, Moscow, ul. Shkuleva, d. 4

V. A Kosov

Komi Republican Oncology Dispensary

Email: zinaidakosova@yandex.ru
врач уролог-онколог, вед. специалист ГУ КРОД 167904, Russian Federation, Syktyvkar, Niuvchimskoe sh., d. 46

I. E Pogodina

Vologda Regional Clinical Hospital №2

Email: utk-irina@yandex.ru
канд. мед. наук, врач-патоморфолог патологоанатомического отд-ния БУЗ ВО ВОКБ №2 162602, Russian Federation, Cherepovets, ul. Danilova, d. 15

D. N Kolbasov

City Clinical Hospital №68 of the Department of Health of Moscow

Email: urology68@rambler.ru
канд. мед. наук, врач-уролог, зав. урологическим отд-нием ГБУЗ ГКБ №68 109263, Russian Federation, Moscow, ul. Shkuleva, d. 4

References

  1. Клиническая онкоурология. Под ред. Б.П.Матвеева. М.: Вердана, 2003; с. 195-407.
  2. Harald zur Hausen. Infections causing human cancer. Wiley - VCH Verlag GmbH and Co. KGA, Weinheim, 2006; p. 517.
  3. Terao S. Shirakawa T, Goda K et al. Recombinant inter; eukin-2 enhanced the antitumor effect of ADV/RSV-HSV-tk/ACV therapy in a murine bladder cancer model. Anticancer Res 2005; 25 (4): 2757-60.
  4. Sharma P, Callahan M.K, Bono P et al. Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open - label, two - stage, multi - arm, phase 1/2 trial.
  5. He S, Nakada D, Morrison S.J. Mechanisms of stem cell self - renewal. Annu Rev Cell Dev Biol 2009; 25: 377-406. doi: 10.1146/annurev.cellbio.042308.113248.
  6. Немцова М.В., Кушлинский Н.Е. Молекулярный патогенез рака мочевого пузыря. Альманах клин. медицины. 2015; 41: 79-88.
  7. Melnick M, Jaskoll T. CMV-induced embryonic mouse organ of Corti dysplasia: network architecture of dysfunctional lateral inhibition. Birth Defects Res A Clin Mol Teratol 2015; 103 (7): 573-82.
  8. Michelson S, Alcami J, Kim S.J et al. Human cytomegalovirus infection induces transcription and secretion of transforming growth factor beta 1. J Virol 1994; 68: 5730-7.
  9. Kwon Y.J, Kim D.J, Kim J.H et al. Human cytomegalovirus (HCMV) infection in osteosarcoma cell line suppresses GM-CSF production by induction of TGF-beta. Microbiol Immunol 2004; 48: 195-9.
  10. Wan X.X, Yi H, Qu J.Q et al. Integrated analysis of the differential cellular and EBV miRNA expression profiles in microdissected nasopharyngeal carcinoma and non - cancerous nasopharyngeal tissues. Oncol Rep 2015; 34 (5): 2585-601.
  11. Gulley M.L. Genomic assays for Epstein - Barr virus - positive gastric adenocarcinoma. Exp Mol Med 2015; 47: e134.
  12. Liang Q, Yao X, Tang S et al. Integrative identification of Epstein-Barr virus - associated mutations and epigenetic alterations in gastric cancer. Gastroenterology 2014; 147 (6): 1350-62.
  13. Андреева Ю.Ю., Данилова Н.В., Завалишина Л.Э. и др. Опухоли мочевого пузыря. Морфологическая диагностика и генетика. Руководство для врачей. Под ред. Ю.Ю.Андреевой, Г.А.Франка. М.: РМАПО, 2011.
  14. Epstein J.I, Reuter V.E, Amin M.B. Biopsy interpretation of the bladder. 2-nd Ed. Philadelphia: Lippincott Williams & Wilkins, 2004; p. 271.
  15. Chow N, Cairns P, Eisenberger C.F et al. Papillary urothelial hyperplasia is a clonal precursor to papillary transitional cell bladder cancer. Int J Cancer 2000; 89: 514.
  16. Powles T et al. Inhibition of PD-L1 by MPDL3280A leads to clinical activity in pts with metastatic urothelial bladder cancer (UBC). ASCO Annual Meeting 2014.
  17. Fukayama M, Hino R, Uozaki H. Epstein-Barr virus and gastric carcinoma: virus - host interactions leading to carcinoma. Cancer Sci 2008; 99 (9): 1726-33.

Copyright (c) 2017 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies